|
YTHDF1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.58210000655856E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
6.13250006331612E-10 |
| Normal-vs-Stage2 |
1.650210E-02 |
| Normal-vs-Stage3 |
7.96789999535363E-08 |
| Normal-vs-Stage4 |
2.57349999999157E-06 |
| Stage1-vs-Stage2 |
1.180230E-01 |
| Stage1-vs-Stage3 |
7.666000E-01 |
| Stage1-vs-Stage4 |
8.041200E-01 |
| Stage2-vs-Stage3 |
1.066580E-01 |
| Stage2-vs-Stage4 |
1.287220E-01 |
| Stage3-vs-Stage4 |
9.867200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.80799997195891E-09 |
| Normal-vs-AfricanAmerican |
1.318060E-02 |
| Normal-vs-Asian |
2.3228999999958E-05 |
| Caucasian-vs-AfricanAmerican |
2.615400E-01 |
| Caucasian-vs-Asian |
6.015600E-01 |
| AfricanAmerican-vs-Asian |
5.381400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.53176999999616E-05 |
| Normal-vs-Female |
6.78289979738622E-10 |
| Male-vs-Female |
1.053380E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.21649999968088E-08 |
| Normal-vs-Age(41-60Yrs) |
3.40300000400973E-08 |
| Normal-vs-Age(61-80Yrs) |
3.612500E-04 |
| Normal-vs-Age(81-100Yrs) |
5.369800E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.385400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.075500E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.139000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.644600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.324800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.996400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.820500E-03 |
| Classical-VS-Follicular |
5.427400E-01 |
| Classical-VS-Other |
1.239560E-01 |
| Classical-VS-Normal |
2.80080000003569E-06 |
| Tall-VS-Follicular |
1.597160E-03 |
| Tall-VS-Other |
9.863600E-01 |
| Tall-VS-Normal |
1.58500002012119E-09 |
| Follicular-VS-Other |
1.976590E-01 |
| Follicular-VS-Normal |
8.196300E-04 |
| Other-VS-Normal |
2.721600E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.01209999994845E-06 |
| Normal-vs-N1 |
2.95250000004188E-08 |
| N0-vs-N1 |
3.596500E-02 |
|
|
